| Primary hepatic cancer with the features of obscure onset and rapid progress takes the second place in the mortality only after the lung cancer.Therefore, it is of great significance to conduct a system research on the precipitating factor, clinical characteristics and 2 years survival rate of the liver cancer patients in order to improve the treatment with integrative Chinese and Western medicine on PHC and give the prognosis accurately and objectively.[Objective]1. The paper intends to get a systematic data of the clinical features, overall and different phase fatality rate and valuable indicators for prognosis.2. By a retrospective study, the paper intends to study the two years fatality rate of the patients, who are treated by the integrative Chinese and Western medicine-Fuzhengj ieduxiaoj ifang.3. The paper intends to study the mechanism of the Fuzhengj ieduxiaoj ifang in the improvement of two years fatality rate.[Method]1. The data of the patients diagnosed with liver cancer were collected from the Ditan Hospital affiliated to Capital Medical University. The data was dated from October,2008 to December,2012, totally 368 patients. Epidata data base was established and the indicators like age, gender, biochemical index and fatality rate are analyzed descriptively. Then the paper obtained the related indicators of fatality rate utilizing the analysis method of single and multiple factor of COX.2. By retrospective research, based on the therapeutic methods, the patients falls into two groups. One group was treated by the Fuzhengj ieduxiaoj ifang, and the other group is treated by the western medicine. Overall and different phases fatality rates were compared and the so did the remission rate of solid tumor and median survival time.3. Prognostic indicators at different time points in the two groups were compared as well.[Result]1. Among the 368 patients, the gender ratio(female:male) is 4.94:1. Men over forty years old possess a higher risk of PHC.87.54% patients of PHC originate from hepatitis B or liver cirrhosis induced by hepatitis B. the fatality rate of liver cirrhosis induced by alcohol is 58.82%, which is highest among all the PHC.2. The 2 years fatality rate is 32.88%. There are 11 patients in the zero phase of BCLC, and nobody died. The number of patients in the A phase of BCLC is 215, and its fatality fate is 9.77%. The number of patients in the B phase of BCLC is 63, and its fatality rate is 39.68%. The number of patients in D phase is 21, and its fatality rate is 90.74%.3. The COX analysis of single factor reveals there were significant differences (P<0.05) in the following indicators between the survival group and the death group, including smoking history, alcohol history, base line AST, ALB, PTA, TBIL, GGT, ALP, CHE, TBA, WBC, NC, LC, NLR, Hb, AFP (≥ 400 μ g/L), Meld grade, classification of Child, and phases of BCLC, The COX analysis of mulitple factor reveals that there were a great influence of following factors on the prognosis, including base line AST, ALB, PTA, TBIL, GGT, ALP, CHE, TBA, WBC, NC, LC, NLR, Hb, AFP(≥ 400 μ g/L),classification of Child-Pugh, and phase of BCLC. Specifically, the ALB, PTA are the protective factors. The phase of BCLC,GGT, NLR, AFP (≥ 400 μg/L) and Child-Pugh classification are dangerous factors. The three critical periods below the ROC curve are the phase of BCLC(0.872), NLR (0.787), GGT (0.704).4. The fatality rate:based on the different treatment methods, the patients are divided into two groups,67 patients in the group of Fuzhengjieduxiaojifang and 48 patients in the group of western medicine. The fatality rates of the two groups are 25.27% and 68.75% respectively. Therefore, the fatality rate of the Fuzhengjieduxiaojifang group is significangly lower than the western medicine group (P< 0.0001). In the three periods of BCLC,O, A and B, there are 55 patients in the group of Fuzhengjieduxiaojifang, among which 7 patients died with the fatality rate of 12.7%. Comparatively, there are 21 patients in the group of western medicine, among which 21 died, and fatality rate is 33.3%. Hence, the fatality rate of the Fuzhengjieduxiaojifang group is significantly lower than the western medicine group (P=0.0314). In the BCLC phase of C and D, however, the fatality rate of the Fuzhengjieduxiaojifang group is significantly higher the western medicine group(50% vs 18.2%, P=0.044).5. Remission rate of solid tumor:in the three periods of BCLC,O,A and B, the group of Fuzhengxiaojifang is significantly higher than the group of western medicine(49.09% vs 19.05%, P=0.017). Similar results are showed in the BCLC phase of C and D(50% vs 18.2%).6. Median survival time:There was significantly difference in the median survival time between Fufangxiaojifang and western medicine groups which are 11.5 months and 6 months respectively(P=0.002).7. In the three periods of BCLC,O,A and B, the base lines of NLR of the two groups had no significantly difference (P=0.476). There were significantly difference (P< 0.05) in the comparison of the NLR in the western medicine group to the base line at the time points of the sixth, twelfth, eighteenth and Twenty-fourth month, which showed an ascending trend. In contrast, for the group of Fufangxiaojifang, the NLR did not rise obviously compared to the base line at the sixth, twelfth, eighteenth month time point and had not significant difference (P > 0.05). The significant difference appeared in the Twenty-fourth month(P< 0.05) and began to rise. At the same time mentioned above, the NLR of Fufangxiaojifang group is significantly lower than the western medicine group (P<0.05).[Conclusion]1. The base line of GGT, NLR, classification of Child-Pugh and phase of BCLC exert a great influence on the survival of patients with PHC. In the indicators of serology, NLR showed the most important influence on the two years survival of patients with PHC.2. Fuzhengxiaojifang can raise the two years fatality rate of the patients, improve the remission rate of solid tumor, and prolong the median survival time, especially for the patients in the BCLC phase of 0+A+B.3. In the BCLC phase of 0+A+B, Fuzhengxiaojifang can lower NLR by relieving inflammation and action of immune system, thus increasing the 2 years survival rate of the patients.
|
PDF Full Text Request